Attached files
| file | filename |
|---|---|
| 8-K - SAVIENT PHARMACEUTICALS INC | rrd327021.htm |
[MCGLADREY & PULLEN LETTERHEAD]
December 2, 2011
U.S. Securities and Exchange Commission
Washington, DC 20549
Re: Savient Pharmaceuticals, Inc.
File No. 0-15313
Commissioners:
We have read Savient Pharmaceuticals, Inc's statements included under Item 4.01 of its Form 8-K filed on December 2, 2011 and we agree with such statements concerning our firm.
/s/ McGladrey & Pullen, LLP
McGladrey & Pullen, LLP
[MCGLADREY & PULLEN LETTERHEAD]
December 2, 2011
Mr. Stephen O. Jaeger
Chairman Audit and Finance Committee
Savient Pharmaceuticals, Inc.
One Tower Center
East Brunswick, New Jersey 08816
Dear Mr. Jaeger:
This is to confirm that the client-auditor relationship between Savient Pharmaceuticals, Inc. (U.S. Securities and Exchange Commission File No. 0-15313) and McGladrey & Pullen, LLP, independent registered public accounting firm, has ceased.
Very truly yours,
/s/ McGladrey & Pullen, LLP
McGladrey & Pullen, LLP
cc: Office of the Chief Accountant
PCAOB Letter File
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549